Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
AC1Q3QWB
i
Other names:
AC1Q3QWB, AQB
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(2)
News
Trials
Company:
Tianjin Medical University General Hospital
Drug class:
HOTAIR inhibitor
‹
›
Associations
(2)
News
Trials
VERI cancer hierarchy
Reset Filters
SOX17 overexpression
Endometrial Cancer
SOX17 overexpression
Endometrial Cancer
tazemetostat + AC1Q3QWB
Sensitive: D – Preclinical
tazemetostat + AC1Q3QWB
Sensitive
:
D
tazemetostat + AC1Q3QWB
Sensitive: D – Preclinical
tazemetostat + AC1Q3QWB
Sensitive
:
D
CDKN1A overexpression
Endometrial Cancer
CDKN1A overexpression
Endometrial Cancer
tazemetostat + AC1Q3QWB
Sensitive: D – Preclinical
tazemetostat + AC1Q3QWB
Sensitive
:
D
tazemetostat + AC1Q3QWB
Sensitive: D – Preclinical
tazemetostat + AC1Q3QWB
Sensitive
:
D
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.